Legend Biotech Corp

Legend Biotech Corp (LEGN) priced its initial public offering on Jun 8, 2020 at $23.00 per ADS, raising $423.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.97B. Morgan Stanley was lead-left underwriter, joined by J.P. Morgan and Jefferies. Cooley, Harneys and Jones Day advised the company and Davis Polk, JunHe and Jingtian & Gongcheng advised the underwriters.

Legend Biotech Corp is a clinical-stage biopharmaceutical company developing cell therapies for oncology and other indications, with over 650 employees in the United States, China and Europe. Its lead candidate, a CAR T cell therapy for multiple myeloma, is being developed jointly with Janssen Biotech.

Status

IPO

Ticker

LEGN

Exchange

Nasdaq Global Select

Priced

Jun 8, 2020

IPO price

$23.00 per ADS

Raised

$423.8M

Market cap at IPO price

$2.97B

First filed

May 13, 2020

Underwriters

Morgan Stanley, J.P. Morgan and Jefferies

Company counsel

Cooley, Harneys and Jones Day

Underwriters' counsel

Davis Polk, JunHe and Jingtian & Gongcheng

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.